Enhertu Growth Offsets Wainua Setback for AstraZeneca

What happened

AstraZeneca's upcoming Q2 2026 results are expected to show continued strong performance in oncology, led by Enhertu which generated $831 million in Q1 2026 revenue, up 39% year-over-year. This growth underscores the resilience of AstraZeneca's oncology franchise despite the setback from Wainua, which faced a regulatory or trial-related disappointment. The company's deep pipeline and label expansions have helped maintain momentum, offsetting isolated program failures. However, the latest DeepValue analysis maintains a WAIT rating, highlighting that the $80B revenue ambition by 2030 remains dependent on consistent regulatory approvals and positive trial readouts. The stock currently trades at $188, near the upper end of the attractive entry range, leaving limited upside without further de-risking of pipeline variables.

Implication

AstraZeneca's oncology engine remains durable, with Enhertu driving meaningful revenue growth. However, the investment thesis hinges on the overall pipeline net productivity outweighing attrition like Wainua. The WAIT rating is justified by the premium valuation (28x P/E) and the need for confirmatory evidence that regulatory approvals continue to outpace setbacks. Investors should monitor Q2 results for ongoing oncology momentum and any updates on pipeline risk. A disciplined entry near $170 offers a better risk-reward, as the long-term growth narrative is intact but near-term catalysts are insufficient to justify current prices.

Thesis delta

No material shift in thesis. The article reinforces the existing view that oncology momentum is strong but the overall pipeline faces headwinds. The WAIT rating remains appropriate. The key variable is whether Enhertu's growth can continue to offset other pipeline disappointments and sustain the multiple.